Gainers
Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion.
EQRx Inc (NASDAQ: EQRX), along with its partner CStone Pharmaceuticals has announced data from Phase 3 GEMSTONE-302 trial of sugemalimab plus chemotherapy as a first-line treatment for stage IV non-small cell lung cancer (NSCLC).
Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung cancer (NSCLC) after
EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced it has signed a non-binding
CM Life Sciences III Inc (NASDAQ: CMLT), the third SPAC backed by Eli Casdin’s Casdin Capital LLC and Keith Meister’s Corvex Management LP, is set to merge with EQRx Inc (NASDAQ: EQRX).
The stock will list on NASDAQ under the EQRX symbol.